HM2021-31: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) B-Cell Non-Hodgkin Lymphoma (B-NHL) - able to walk and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- previous treatment with polatuzumab vedotin, glofitamab or mosunetuzumab - stem cell transplant within 60 days prior to start of study drug - Human immunodeficiency virus (HIV) seropositive - women who are pregnant or breast feeding

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), B-Cell Non-Hodgkin Lymphoma, B-NHL

More Information

Description: The purpose of this study is to evaluate if the investigational combination of drug called loncastuximab tesirine in combination with another anti-cancer agent is a safe and effective treatment for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
Study Contact: Riley Stuckey - stuck129@umn.edu
Principal Investigator: Marie Hu
Phase: PHASE1
IRB Number: STUDY00015805